Replies to post #1146 on Momenta Pharmaceuticals, Inc. (MNTA)

[Mpower]

How many think it is pathetic that on June 17th, 2010 (a full month pre FDA mL approval) MNTA was trading at 15.25, and now a full 6 months after approval, the stock is essentially flat.

No TEVA approval before EOY (as Marth spewed in his recent CC's), but somehow MNTA's stock is still flat as Oklahoma.

How do the other 'affected' companies compare?

SNY: Sanofi's stock is ~7.5% higher than it was mL pre-approval (6 months after approval) (+6.35 billion $'s). Pretty phenomenal in light of their shrinking pipeline and challenges to their business.

TEVA: Teva is essentially flat post mL approval, but that performance is not half bad considering they don't have generic lovenox and now have a threat to Copaxone on the horizon.

NVS: 13% higher than it was pre mL approval. NVS kicking butt and taking names. These guys know how to run a company, and I pray they take MNTA out of its misery sooner rather than later. I'd take a buyout @ $25 right now.

IN summary, MNTA's overall performance is abysmal, and i really think CW / MNTA VP's have spent too much time counting their personal fortunes and not enough on time getting the MNTA message out there.

[jbog]

Many MNTA longs were hurt bad this year,

How do you figure Mnta longs were hurt, let alone 'hurt bad' considering the stock is up around 30% this year.

Are you possibly referring to people who bought the bounce, rather than trim into the bounce?

I guess it's all how we define long....